Saturday, December 13, 2025 12/13/2025

Targeting of tumor cell DHHC3 to enhance anti-cancer immunity

Award Number: R01CA237066
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2020
PERIOD OF PERFORMANCE END DATE: 02/28/2025

Group Awards By:

View Award Description

Targeting of tumor cell DHHC3 to enhance anti-cancer immunity - Project Summary Mobilization of both adaptive and innate immune cells has considerable utility in the treatment of breast cancer and other cancers. Here we provide a novel approach. Our central goal is to demonstrate how ablation of the protein acyl transferase, DHHC3, can enhance both adaptive and innate anti-cancer immunity. Towards achieving this goal, we have already shown that ZDHHC3 ablation i) markedly diminishes levels of checkpoint blockade molecule PD-L1 on tumor cells, and ii) disrupts CMTM6, a molecule needed to maintain PD-L1 expression, such that CMTM6 palmitoylation is abolished and subcellular localization markedly altered. Furthermore, iii) restoration with wild type DHHC3, but not enzymatically inactive DHHC3, restores PD-L1 levels. In addition, iv) ZDHHC3 ablation markedly reduces tumor xenograft growth in nude mice (but not in vitro) by a mechanism involving elevated oxidative stress, senescence, and tumor clearance by innate immune cells. Because the DHHC3 enzyme may regulate both adaptive and innate anti-cancer immunity, but is not needed for normal mouse physiology, it may be a useful therapeutic target. Our central guiding hypotheses are i) that DHHC3 ablation prevents CMTM6 palmitoylation, leading to degradation of unprotected PD- L1 on tumor cells, which enhances adaptive immunity and ii) that DHHC3 ablation also enhances innate immunity, with key regulators of oxidative stress (e.g. ERGIC3, TXNIP) and innate immune cells (e.g. NK cells) playing major roles. These hypotheses will be tested as follows: Aim 1, We will use a variety of in vitro and in vivo experiments to establish the extent to which DHHC3 ablation enhances adaptive immunity by a mechanism involving loss of CMTM6 palmitoylation leading to diminished PD-L1 expression. Aim 2, We will assess relative in vivo effects of mammary tumor cell DHHC3 ablation on innate and adaptive anti-breast cancer immunity, and we will evaluate key contributions of oxidative stress, senescence, and NK cells to innate immunity. Expected Impact: Results should support the utility of DHHC3 as a novel tumor target in breast cancer and other cancers, as DHHC3 ablation from tumor cells simultaneously enhances both adaptive and innate immunity, with CMTM6, PD-L1, oxidative stress, and NK cells playing key roles.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$18,980 )
2025	2024	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	000	5	6/11/2025	NON-COMPETING CONTINUATION	-$18,980
														Subtotal = -$18,980

Issue Date FY: 2024 ( Subtotal = $380,201 )
2024	2024	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	000	5	2/5/2024	NON-COMPETING CONTINUATION	$360,191
2024	2024	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Biology Research	001	5	4/16/2024	NON-COMPETING CONTINUATION	$20,010
														Subtotal = $380,201

Issue Date FY: 2023 ( Subtotal = $392,207 )
2023	2023	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Biology Research	000	4	2/23/2023	NON-COMPETING CONTINUATION	$392,207
														Subtotal = $392,207

Issue Date FY: 2022 ( Subtotal = $392,207 )
2022	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Biology Research	001	3	5/25/2022	NON-COMPETING CONTINUATION	$32,018
2022	2022	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Biology Research	000	3	2/23/2022	NON-COMPETING CONTINUATION	$360,189
														Subtotal = $392,207

Issue Date FY: 2021 ( Subtotal = $400,211 )
2021	2021	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Biology Research	000	2	2/22/2021	NON-COMPETING CONTINUATION	$400,211
														Subtotal = $400,211

Issue Date FY: 2020 ( Subtotal = $400,211 )
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Biology Research	000	1	2/28/2020	NEW	$400,211
														Subtotal = $400,211

Grand Total All Awards = $1,946,057

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting of tumor cell DHHC3 to enhance anti-cancer immunity

Award Number: R01CA237066

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2020

PERIOD OF PERFORMANCE END DATE: 02/28/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer